Hopper et al. [29] detected a deleterious CYP17A1 germline mutation, p.R239X, in three sisters with early-onset breast cancer, and the breast cancer risk associated with this mutation has been reported to be more than 20 times the population incidence. Here, CYP17A1 is linked to breast carcinoma.